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ABSTRACT 
Introduction 
South Africa is estimated to have the largest number of HIV infected adults in Southern 
Africa with a higher HIV prevalence in females compared to males. While significant 
reductions in morbidity and mortality due to HIV and AIDS have been realized for over a 
decade internationally, HIV treatment involving highly active antiretroviral therapy 
(HAART) is still a relatively new phenomenon in this country and gender differences in 
HIV outcomes between males and females in South Africa have not been previously well 
described. This study aimed to determine and describe gender differences in clinical and 
immunological outcomes in a population of HIV infected South African adults initiated 
on HAART. 
 
Materials and Methods 
This retrospective data analysis reviewed 6,617 HIV-infected adults initiated on HAART 
at the Themba Lethu Clinic, an urban public-sector antiretroviral rollout facility in 
Johannesburg, South Africa between 1
st
 April 2004 and 31
st
 March 2007. Clinical data 
from these antiretroviral naïve patients was analysed for gender differences in mortality, 
rates of loss to follow up, CD4 cell count response, virologic suppression and weight 
gain. Cox regression models and logistic regression models were used to estimate hazard 
ratios (HR) and odds ratios (OR), respectively, for associations between gender and 
outcomes. Models were adjusted for age and baseline CD4 count. 
 
Results 
At baseline, 4,388 (66.3%) women were significantly younger (p<0.0001) and  
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less likely to be employed than the 2,229 (33.7%) men (p<0.001). Furthermore, women 
had significantly higher baseline CD4 counts (p<0.0001) and higher body mass index 
(BMI) (p<0.0001). Males experienced significantly reduced survival compared to females 
(p=0.0053) by Kaplan-Meier analysis. In adjusted multivariate analysis, men were 22% 
more likely to die or become lost to follow up than women [HR = 1.22 (95% CI 1.06 - 
1.39]. The period with the highest risk of mortality or loss to follow up was within six 
months of starting HAART.  
Female gender was associated with better CD4 count response. In multivariate analysis 
adjusted for age and baseline CD4 count, women were 35% more likely to achieve a 100 
cell increase in CD4 count at four months after initiation of HAART [OR =1.35 (95% CI 
= 1.19 -1.54)] and 45% more likely to increase their CD4 counts by 100 cells/mm
3
 after 
ten months on HAART [OR =1.42 (95% CI = 1.20 -1.68)] when compared to men. 
Women were also more likely to achieve virologic suppression at ten months post 
HAART initiation [OR =1.54 (95% CI =1.21-1.97)] and were more likely to have gained 
weight after four months on treatment than males [OR = 1.26 (95% CI = 1.07–1.49)] after 
adjusting for age, baseline CD4 count and baseline BMI.  
 
Conclusions 
Women had significant advantages over men in terms of short-term clinical and 
immunological outcomes. Earlier access treatment for men should be facilitated and 
adherence should be promoted once on treatment. Further research is required to 
determine if these gender differences persist during long-term HAART.  
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CHAPTER ONE: INTRODUCTION 
 
 
In this chapter the significance of the HIV epidemic in South Africa is reviewed. Sources 
and implications of gender inequalities amongst HIV infected persons are explored. The 
published literature on gender differences in clinical and immunological outcomes of 
HIV infection is reviewed and the chapter ends with the aims and objectives of the study 
described in this Research Report. 
 
Background 
The use of highly active antiretroviral therapy (HAART), since its advent in 1996, has 
resulted in significant reductions in mortality from HIV-related illness worldwide [1, 2]. 
Developing countries including those in sub-Saharan Africa have shown similar 
improvements in survival and clinical outcomes in HIV-infected individuals receiving 
HAART compared to developed countries despite resource poor settings [3]. 
 
However, there are significant differences in access to antiretroviral therapy between the 
developed and the developing world, leaving many patients in resource-limited countries 
with no access to antiretroviral therapy despite a decade of availability of these 
potentially life-saving drugs [4]. Moreover, the poorest and most vulnerable sections of 
society in these resource-limited countries are the least likely to access HAART; sections 
in which women are often over-represented. In such settings one may expect to see 
significant differences in survival and clinical outcomes between HIV infected women 
and men.  
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South Africa is one such country. South Africa is estimated to have the largest number of 
HIV infected adults in Southern Africa [5] with a higher HIV prevalence in females 
compared to males (female: male ratio estimated between 1.2 and 2.3) [6]. The 
government antiretroviral rollout was officially launched in South Africa in 2004; 
therefore, comprehensive HIV treatment involving HAART is still relatively new in this 
country. It is for this reason that gender differences in HIV outcomes in South Africa 
have not been well described. 
 
Additionally, if such gender differences in HIV outcomes based on access to treatment 
exist, it is important to determine if such differences persist when access to treatment is 
equal. If this is the case, it may warrant a re-evaluation of the current single guideline for 
both genders regarding treatment of HIV involving HAART to address these differences. 
 
Statement of the problem 
Gender differences in HIV outcomes may persist despite equal access to HAART. This 
has not been well described in South African patients receiving HAART and may have an 
impact on the treatment guidelines recommended for men and women receiving HAART. 
 
Justification for the study 
HIV care, including the provision of antiretroviral therapy, places an enormous financial 
burden on health care especially in resource-limited settings. It is, therefore, essential to 
know if there is a difference in HIV outcomes between men and women receiving 
HAART so that resources may be used optimally to maximize positive health outcomes.  
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The researcher is unaware of any published study examining such gender differences in 
HIV outcomes for patients receiving HAART in South Africa. There have been 
conflicting results from studies done in other countries with some showing significant 
gender differences in HIV outcomes [10-13] and others which found no differences 
between males and females [8-9,] once HAART is initiated.  
 
The published literature reviewed has studied mostly white men who have sex with men 
(MSM) or IV drug users in North America and Europe and the results of these studies 
may differ to studies of South African HIV infected individuals where transmission 
occurs largely through heterosexual intercourse and women have a higher prevalence of 
HIV infection than men.  
 
Literature review 
 
Introduction 
The prognosis for HIV-infected patients has considerably improved since the introduction 
of HAART into the management of HIV infection. Disease progression and mortality 
rates have dropped significantly with use of HAART worldwide [1, 2] and individuals 
infected with HIV can expect a quality and prolongation of life that would not have been 
possible in the pre-HAART era. HIV incidence rates remain high, particularly in sub-
Saharan Africa despite mass education and prevention campaigns [7], resulting in ever-
increasing numbers of individuals requiring treatment with HAART.  
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Access to Antiretrovirals 
Yet there appears to be inequality in the distribution of HAART, not only between 
developing and developed countries, but also between men and women even when access 
to these potentially life saving drug is secured [8, 14]. Mocroft et al [8] showed that 
despite free access to antiretrovirals, women were significantly less likely than men to 
start antiretroviral therapy and particularly less likely to receive a protease-inhibitor 
containing regimen than their male counterparts. Proposed reasons for this disparity 
included the poorer socio-economic circumstances that women may experience as well as 
family commitments and lack of child care that may be obstacles that women experience 
in keeping HIV clinic appointments.  
 
Clinical Presentation 
However, when women do present to clinics for initiation of HAART, they do so with 
significantly higher baseline CD4 counts and with a lower proportion of AIDS defining 
illnesses than men [8]. Women have also been reported in other studies to have lower 
baseline viral loads, higher baseline CD4 counts and are less likely to have an AIDS 
diagnosis at the time of starting HAART [11]. This suggests that women may display 
earlier help-seeking behaviour compared to men. It must also be considered that there is 
evidence of biological differences in the normal range of CD4 counts between men and 
women (analogous to the differing normal ranges of haemoglobin levels according to 
gender) with women having higher CD4 counts than their males counterparts in HIV 
negative individuals and in HIV positive individuals even up to 5 years after infection 
[11].  
 5 
Clinical Outcomes after Initiation of HAART 
The debate over potential gender differences in the effect of clinical outcome after 
starting HAART is ongoing and the results are conflicting. Some studies have shown a 
possible benefit for women compared with men in the rate of outcomes after HAART use 
[10]. This includes decreased rates of hospital admissions, lower rates of progression to 
new AIDS defining illness, faster rates of achieving virologic suppression. These results 
may have been limited by the inability to adjust for adherence rates which were suspected 
to be better in women but not available for analysis in the data. HIV infected males have 
also been shown to experience higher mortality rates [16] and have a greater risk of 
premature atherosclerosis and cardiovascular events than their female HIV counterparts 
in adjusted analyses [18]. 
 
Other studies have shown the converse to be true - suggesting that women receiving 
HAART may fare less well than their male counterparts. The women in these studies had 
a higher risk of virological rebound [11], increased hospitalization rates [11, 12] and 
higher likelihood of adverse effects and toxicities of antiretroviral drugs [13]. These 
studies did consider the possibility that the gender differences were more likely to be as a 
result of inequality in access to care rather than in a fundamental biological difference in 
response to treatment. Other theories postulate that women have poorer outcomes as they 
are more likely than men to encounter social challenges such as having difficulty taking 
HAART openly at home due to the stigma associated with HIV infection [15]. 
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Still other studies have shown no difference at all between the genders in terms of disease 
progression and immunological or virological response to a HAART treatment regimen 
[8-9, 17, 19]. However most of these studies had very small numbers of women included 
in the analyses which may have decreased these studies’ power to detect differences 
between men and women. 
 
Studies evaluating weight gain after initiation of HAART have shown moderate increases 
in weight for those receiving HAART compared to treatment naïve patients [21, 22]. 
Study participants with lower baseline CD4 counts in these studies tended to present with 
lower baseline weight and BMI (body mass index) but also showed greater weight gain 
within the first four months on treatment. However, no significant gender differences in 
weight gain were reported. 
 
Conclusion 
While previous research provides a useful background to the possible gender differences 
that may exist in South African patients receiving HAART, the results of these studies 
may not be consistently reproduced in the South African HIV-infected population for a 
number of reasons. Firstly, while most of the published literature studied mostly white 
MSMs and IV drug users with only a small proportion of infected females, South African 
HIV transmission occurs mainly through heterosexual contact and a larger proportion of 
women are infected than men. Additionally, the nadir CD4 count for starting HAART in 
some of the studies was 500 cells/mm3, much higher than the 200 cells/mm3 cutoff 
currently used in South Africa. 
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In conclusion, gender differences in HIV outcomes may be present amongst South 
African HIV-infected adults receiving HAART, but has not been well described as yet. 
Hence this research project to investigate and describe potential gender differences in the 
clinical and immunological outcomes amongst HIV-infected adults receiving HAART 
from a public-sector antiretroviral rollout clinic based in Johannesburg, South Africa. 
  
Definition of terms 
 
HAART  
Highly active antiretroviral therapy is defined as combination of three or more nucleoside 
reverse transcriptase inhibitors (NRTI) or a combination of two NRTIs plus a protease 
inhibitor or a non-nucleoside reverse transcriptase inhibitor (NNRTI). 
 
HIV outcomes  
This term encompasses clinical outcomes (death and weight gain), immunologic 
responses to HAART (as measured by an increase in CD4 count) and virologic response 
(defined as a decrease in HIV viral load to undetectable limits).  
 
BMI  
Body mass index is an anthropometric measure which is calculated as follows: weight in 
kilograms divided by the square of height in metres. 
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Study Objectives 
 
General objective 
To determine and describe gender differences in HIV outcomes in a population of HIV 
infected South African adults. 
 
Specific objectives 
 To describe the gender distribution of South African adult HIV infected patients 
receiving HAART  
 To measure differences in weight gain, mortality rates and rates of loss to follow-up 
between male and female HIV infected South African adults taking HAART  
 To determine if men are more likely to show short term immune reconstitution to 
HIV once HAART is initiated than women as measured by response in CD4 count 
and viral load suppression  
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CHAPTER TWO: METHODOLOGY 
 
Introduction  
In this chapter, the study design and methodology are presented. The study population is 
described and selection of the study sample is explained. The data collection system at 
the study site is described and details of the variables to be analysed are presented. 
Definition of each clinical and immunological outcome of interest is given and the 
chapter ends with a review of the data analysis plan and ethical considerations of this 
project. 
 
Study Design 
This study is a retrospective analytic cohort study conducted as a secondary data analysis 
of data collected from HIV positive adults at the Themba Lethu Clinic. 
 
Study site 
The Themba Lethu Clinic is an urban antiretroviral rollout site based at Helen Joseph 
Hospital, a provincial public hospital in Gauteng, South Africa. Since its inception in 
2004, the clinic has enrolled over 8000 HIV infected adults from Johannesburg and 
environs. Currently, the clinic provides free antiretroviral therapy to more than 7000 of 
these patients according to the South African National Department of Health’s guidelines 
on rollout of antiretroviral therapy [20]. This site was chosen as the Themba Lethu Clinic 
is one of the largest public antiretroviral rollout sites and its population can be considered 
representative of urban populations accessing antiretroviral therapy in the public sector. 
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Additionally the clinical data from the patients’ records at this site is captured 
electronically and, as such, was one of the few sites with data available and accessible for 
secondary analysis. 
 
Study population 
The study population consists of the 9,834 HIV positive adults enrolled at the Themba 
Lethu Clinic since its inception on 1
st
 April 2004.  
 
Study sample 
The study sample consists of 6,617 male and female adults initiated on HAART at the 
Themba Lethu Clinic between 1
st
 April 2004 and 31
st
 March 2007 who met the following 
inclusion criteria: 
 
• Patients older than 18 years of age at the time of enrollment in the clinic 
• HAART naïve prior to the initiation visit at the clinic 
• Blood results were available for CD4 count tested at the initiation (baseline) visit  
 
Exclusion criteria: 
• Patients transferred in from other clinics or rollout sites already initiated on 
HAART 
 
Details of the exclusion process are outlined in Chapter three. 
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Measurement 
The Themba Lethu clinic records both demographic and clinical patient information on 
an electronic database, Therapy Edge. Data are captured from the patient files by trained 
data capturers after each clinic visit. The patients’ demographic and contact details are 
recorded at the initiation visit on the “ARV Initiation Form” (Appendix A). At every visit 
the patient’s vitals and weight are recorded as well as any symptoms and new diagnoses 
made on the “Follow-up Visit Form” (Appendix B). Additionally, blood tests results for 
CD4 count, HIV viral load, full blood counts as well as liver function tests which are 
tested at each scheduled visit (four months after initiation and six monthly thereafter) are 
collected and entered onto the database.  Any clinically indicated additional 
investigations and results are also recorded on the database. All data used in the study 
was obtained from variables already captured on this electronic database. All data was 
de-identified and unique study numbers were allocated to each individual before the data 
was provided for analysis. 
 
Study variables 
The exposure to be measured is gender and the outcomes of interest include clinical 
outcomes (weight gain, death or loss to follow up) and immunological outcomes after 
initiation of HAART. Immunological outcomes were measured using CD4 count 
response and HIV viral load suppression. The outcomes are defined as follows: 
 
 Death or loss to follow up using confirmed date of death recorded on the database 
or, in the case of loss to follow up, the date of last clinic visit 
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 Weight gain defined as an increase in body weight of five percent or more from 
baseline weight at initiation on HAART or a five kilogram increase in weight 
after initiating HAART 
 CD4 count response defined as an increase in CD4 count from the baseline CD4 
count, or a 50% increase in CD4 count or achieving a 100 cell rise in CD4 count 
after initiation of HAART. 
 HIV viral load suppression defined as decrease in HIV viral RNA to less than 
400 viral copies after initiating HAART 
 
The outcomes data was provided from the clinic’s electronic database after any 
identifying information is removed. Data was also obtained on the following baseline 
characteristics: age, race, HAART regimen, and socio-economic status (using 
employment status as a proxy). 
 
Data Quality Control 
The data at the Themba Lethu Clinic is captured from the medical records to an electronic 
database via a medical management software system, TherapyEdge-HIV
TM
. The database 
is managed and maintained by a non-profit organization, Right to Care who through a 
team of trained data capturers, capture the data electronically and do quality assurance 
checks. Right to Care and the Clinical HIV Research Unit of the Department of Medicine 
(WITS University) agreed to work with the researcher to create a de-identified dataset 
containing the required fields of interest. Furthermore observations with values which 
seemed implausible were set to missing by the researcher as verification of data was not 
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possible due to the de-identified nature of the data. Variables which were cleaned in this 
way included: 
Height – plausible values were deemed to be between 135 and 200 centimetres 
Weight - plausible values were deemed to be between 30 and 200 kilograms 
CD4 counts – these are reported as integers by the laboratory and so values with decimal 
places were considered typing or capturing errors and set to missing 
 
Data processing Methods and Data Analysis 
Data analysis was done using the STATA 9.0 statistical software package. All statistical 
significance was calculated at the 5% confidence level. The baseline characteristics of the 
two exposure groups (males and females) were summarized with descriptive statistics and 
presented in Table 1. Odds ratios or hazard ratios of each outcome were calculated for 
both genders. Univariate analysis of the associations between gender and each outcome 
was done using the Chi squared test for proportions (proportion showing CD4 count 
response or HIV viral load suppression and proportion dead or lost to follow up etc).  
 
Time-to-event analysis was performed using survival techniques including Kaplan-Meier 
estimates, a log rank test and proportional hazards model. Multivariate model building 
was conducted in the following manner:  
• Variables which modified the hazard ratio for the effect of gender on each 
outcome by more than ten percent were included in the multivariate analysis.  
• If no variable modified the effect by more than ten percent then variables from the 
univariate analysis were retained in the model at an alpha of 0.20. 
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Assumptions testing for the models are presented in Appendix E. 
 
Ethical considerations 
The individuals in the study sample were identified by a unique identifier that does not 
relate to the participant’s date of birth. Any personal identifiers were removed prior to the 
data being given to the researcher for secondary analysis and as such, the researcher was 
unable to identify individuals in the sample or to collect informed consent from the 
sample population. The study was conducted according to the Standard Operation 
Procedure (SOP) of the Clinical HIV Research Unit governing the analysis of data from 
the Themba Lethu Clinical Cohort (see Appendix C) which includes inter alia the 
approval of the research protocol by the University of the Witwatersrand Committee for 
Research on Human Subjects (Medical) (see Appendix D) and permission to conduct the 
study from the CEO of Helen Joseph Hospital where the Themba Lethu Clinic is based. 
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CHAPTER THREE: RESULTS 
 
Introduction 
In order to meet the aims and research objectives of this report, the clinical and 
immunological outcomes data was analysed systematically by gender and the results are 
presented in this chapter. The baseline characteristics of the cohort are described and any 
differences in baseline characteristics between the genders measured. The clinical 
outcomes, death and loss-to-follow up are considered next, followed by the 
immunological outcomes (CD4 count and viral load). The chapter ends with the analysis 
of final clinical outcome, weight gain, and a comparison between the genders. 
 
Cohort demographics 
The study population consisted of the 9,834 adults enrolled on the antiretroviral rollout 
programme at the Themba Lethu Clinic between 1 April 2004 and 31 March 2007. Of 
these, 1,146 were excluded from the study because they were transferred into the clinic 
from other antiretroviral treatment programmes, and a further 2,071 subjects were already 
on treatment at the time of enrolling at the Themba Lethu clinic, or they had received 
antiretroviral treatment at some point previously and thus could not be considered 
treatment naïve. The study sample that remained consisted of 6,617 individuals. The 
baseline characteristics of this overall cohort, as well as the baseline characteristics 
compared by gender, are presented in Table 1.  Assumptions testing for normally 
distributed data and t-tests are presented in Appendix E. 
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Table 1: Baseline Characteristics of the Themba Lethu Clinical Cohort at Initiation of 
Antiretroviral therapy 
 
 
 Overall 
N (%)/ x , std 
Males 
N (%)/ x , std 
Females 
N (%)/ x , std 
χ2 (p value) 
Frequency (n, %) 6617 (100) 2229 (33.7) 4388 (66.3)  
Age (years)  
     ( x , std) 
n = 6617 
37.7 (8.6) ‡ 
n = 2229 
39.8 (8.4) ‡ 
n = 4388 
36.6 (8.6) ‡ 
 
14.3 (<0.0001)† 
Employment   (n, %)  
     -  yes  
     -  no 
 
2396 (38.5) 
3823 (61.5) 
 
950 (45.1) 
1156 (54.9) 
 
1446 (35.2) 
2667 (64.8) 
 
 
58.3 (<0.001) 
Initiating ARV regimen (n, %) 
 
     - 1a (3TC, efv, d4T/AZT) 
     - 1b (3TC, d4T, nvp) 
     - any first line incl lopinavir 
     - 2
nd
 line (ddI, AZT, LPV/r) 
     - other 
 
 
4272 (64.6) 
452 (6.8) 
527 (7.6) 
226 (3.4) 
304 (4.6) 
 
 
1484 (66.6) 
122 (5.5) 
160 (7.1) 
73 (3.3) 
110 (4.4) 
 
 
2788 (63.6) 
330 (7.5) 
367(8.4) 
153 (3.5) 
194 (4.9) 
 
 
 
 
 
 
14.366 (0.006) 
Baseline weight (kg)  
     ( x , std) 
n = 5001 
60.1 (13.3) ‡ 
n= 1696 
60.3 (11.0) ‡ 
n = 3305 
59.9 (13.3) ‡ 
 
0.92 (0.3571) † 
Baseline BMI  (kg/m
2
) 
     ( x , std) 
n = 4990 
22.5 (5.0) ‡ 
n = 1694 
20.5 (3.6) ‡ 
n = 3296 
23.4 (5.4) ‡ 
 
-20.0(<0.0001)† 
Baseline BMI (kg/m
2
) (n, %) 
 
      - Underweight (<18.5 ) 
      - Normal (18.5 – 25) 
      - Overweight (>25) 
 
 
2812 (56.4) 
978 (19.6) 
1200 (24.0) 
 
 
1070 (63.2) 
466 (27.5) 
158 (9.3) 
 
 
1742 (52.9) 
512 (15.5) 
1042 (31.6) 
 
 
 
 
334.1 (<0.0001) 
Baseline CD4 count (cells/mm
3
)      
      ( x , std) 
n = 6124 
90 (67) ‡ 
n = 2096 
80.1 (65.5) ‡ 
n = 4028 
95.1 (67.2) ‡ 
 
74.4 (0.0001)† 
Baseline CD4 count (cells/mm3) 
(n, %) - > 100 cells/mm3 
           - 50 – 100 cells/mm3 
           - <50 cells/mm3 
 
2588 (42.3) 
1324 (21.6) 
2212 (36.1) 
 
763 (36.4) 
425 (20.3) 
908 (43.3) 
 
1825 (45.3) 
899 (22.3) 
1304 (32.4) 
 
 
 
74.27  (<0.001) 
Year of initiation  (n, %)  
       - 2004/2005 
       - 2005/2006 
       - 2006/2007 
 
1642 (24.8) 
2230 (33.7) 
2745 (41.5) 
 
501 (22.5) 
728 (32.7) 
1000 (44.8) 
 
1141 (26.0) 
1502 (34.2) 
1745 (39.8) 
 
 
 
8.89 (0.0001) 
 
† z score and associated p values used for continuous variables compared using the student’s t test or 
Kruskal Wallis test as appropriate, assumption testing at the end of the chapter 
‡ Assumption testing for normally distributed data presented in Appendix E.  
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Two thirds of the cohort was female with a female to male ratio of 2:1. The men were 
significantly older than the women and the odds for being employed were 34% less for 
males compared to females (OR = 0.66 95% CI = 0.59; 0.73).  The majority of the cohort 
was initiated on Regimen 1a (lamivudine, stavudine and efavirenz) which is the regimen 
recommended by the DOH guidelines for initiating antiretroviral therapy. Women were 
more likely to be on Regimen 1b (lamivudine, stavudine and nevirapine) or 
lopinavir/ritonavir containing first line regimens than their male counterparts. Very few 
participants were initiated on second line therapy (two NRTI’s and a PI or three NRTI’s). 
 
There was no difference in baseline weight between men and women; however women 
had significantly higher BMI at initiation of treatment than men. Women also had 
significantly higher mean baseline CD4 counts than men (95.1 cells/mm
3
 versus 80.1 
cells/mm
3
 respectively). The overall CD4 count at initiation of HAART for this cohort 
was 90 cells/mm
3
 which is significantly lower than the cutoff CD4 count of 200 
cells/mm
3
. 
 
The enrollment rates at the Themba Lethu Clinic have been increasing steadily over the 
three years since the antiretroviral rollout programme began on the 1
st
 April 2004 with 
over 40% of the overall cohort enrolled between 1
st
 April 2006 and 31
st
 March 2007.  
There have always been a greater proportion of women enrolling on the programme but 
over time, the rates of male enrollments have been increasing and 45% of the male cohort 
was enrolled between 1
st
 April 2006 and 31
st
 March 2007. This has resulted in a change 
in the female to male ratio amongst newly initiated patients over the three years. In the 
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2004/2005 enrollment year the ratio was 2.3: 1; in 2005/2006 the ratio had dropped to 
2.1: 1 and in the last year 2006/2007 the ratio was at its lowest to date at 1.7: 1. This 
increase is depicted in Figure 1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Gender distribution of the Themba Lethu Clinical cohort from 2004 to 2007 
 
Death and Loss-to-follow-up 
Of the 6,617 participants in this cohort, 321 individuals (4.9%) were confirmed dead by 
the end of the study period (31
st
 October 2007). A further 708 (10.8%) were confirmed 
lost to follow up by this time. Patients were considered lost to follow up if they missed 
their next scheduled appointment by more than 90 days or at least 180 days had lapsed 
since their last visit. However, it is certain that some of the patients who are lost to follow 
up are deceased and so it may be more logical to consider patients who are either dead or 
lost to follow up together. Together there were 1,021 (15.4%) patients in this cohort who 
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were lost to follow up or dead by the end of the study period (31
st
 October 2007). All 
three analyses are presented. 
 
1. Death 
There were 6,617 subjects for survival analysis and 321 deaths (4.9% of the total cohort) 
were recorded before the censor date 31
st
 October 2007. Of those who died, 191 (59.5%) 
were female and 130 (40.5%) were male.  The Chi-square test showed that the proportion 
of men who died was significantly greater than the proportion of women who died (χ
2 
= 
7.0080  p = 0.008).  
 
These subjects contributed 12,008.4 person years of observation for analysis during 
which 321 failure events (deaths) occurred. If the hazard function could be assumed to be 
constant, it would be estimated at 0.027 deaths per person-year. Mortality was estimated 
using Kaplan-Meier (KM) survival curves and incidence rates expressed per person-
years. The survival of this cohort by gender, including a risk table demonstrating the 
numbers at risk for selected follow-up durations, is depicted in Figure 2.  
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time 0 6mo 1 yr 18mo 2 yr 2.5 yr 3 yr 
n at risk  
Male 
Female 
 
2229 
4388 
 
2147 
4366 
 
1706 
3503 
 
1233 
2704 
 
826 
1919 
 
523 
1222 
 
227 
502 
 
 
 
Figure 2: Kaplan-Meier survival plots for the Themba Lethu Clinical Cohort by gender 
 
The log-rank test for equality of survivor functions showed that the survival of females 
was significantly greater than that of males (χ
2 
=7.76 p = 0.0053). 
 
The timing of these deaths was investigated and is presented in Table 2. The highest 
mortality occurred in the first three months after initiating treatment (24.1 deaths per 
100,000 person days) and then decreased steadily over time until, after three years on 
treatment, the death rate was 2.1 per 100,000 person days. This trend was consistent for 
Male     
Female     
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both genders. The greatest difference in mortality between men and women occurred 
between three and six months after treatment initiation.  
 
Table 2: Period Incidence rates for mortality at specified time periods after initiation of 
HAART 
 
Time post 
HAART 
initiation 
Overall Period 
Incidence (per 
100,000)  (CI) 
All 
Deaths 
(n) 
Male Period 
Incidence (per 
100,000)  (CI) 
Male 
Deaths 
(n) 
Female Period 
Incidence (per 
100,000)  (CI) 
Female 
Deaths 
(n) 
     
0–3mnths    
 
3-6 mnths 
 
6– 9 mnths 
 
9–12mnths 
  
1 – 2 years 
  
2 – 3 years 
 
  >3 years 
 
24.1  
(20.5 – 28.5) 
11.0 
(8.6 – 14.1) 
7.3  
(5.4 – 9.9) 
4.4  
(2.9 – 6.7) 
2.6  
(1.9 – 3.6) 
1.6  
(0.8 – 2.9) 
2.1  
(0.3 – 15.3) 
 
142 
 
64 
 
41 
 
22 
 
38 
 
10 
 
1 
 
28.3  
(21.8 – 36.8) 
22.0  
(17.8 – 27.2) 
10.1  
(6.5 – 15.9) 
4.8  
(2.4 – 9.6) 
3.3  
(2.0 – 5.5) 
2.1  
(0.8 – 5.6) 
0 
 
56 
 
26 
 
19 
 
8 
 
15 
 
4 
 
0 
 
22.0  
(17.8 – 27.2) 
9.9  
(7.2 – 13.5) 
5.9 
 (3.9 – 8.9) 
4.2  
(2.4 – 7.0) 
2.3 
 (1.5 – 3.5) 
1.3  
(0.6 – 3.0) 
3.2  
(0.4 – 22.4) 
 
86 
 
38 
 
22 
 
14 
 
23 
 
6 
 
1 
  
 
Risk factors for mortality after initiation of HAART were estimated using Cox 
proportional hazards models. Hazard ratios for each variable were calculated and are 
presented in Table 3 for both univariate and multivariate analyses.  In the univariate 
analysis, the hazard of death was 37% greater for men when compared to women. Other 
significant predictors of death in the univariate analysis included age, low baseline 
weight, baseline CD4 count <100 cells/mm
3
 and unsuppressed HIV viral load at four 
months after initiation of HAART.  
Those variables in the univariate analysis which changed the hazard ratio for gender by 
10% or more were entered into the multivariate analysis and retained at α=0.05. The 
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variables included in the final model were sex, age and baseline CD4 count. Interaction 
terms were tested for but no significant interactions were found. Assumption testing for 
these models is presented in Appendix E.  
 
Table 3 : Factors associated with mortality after initiation of HAART 
 
Factor Univariate Model 
Hazard Ratio    ( CI )     p - value 
Multivariate Model 
Hazard Ratio    ( CI)      p - value 
Sex 
     Females  
     Males  
 
Age (in 5 year increments) 
Baseline weight (in 5kg 
increments) 
Baseline CD4 count (in 10 
cells/mm
3 
increments)  
 
Baseline CD4 count (cells/mm
3
) 
            - > 100 cells/mm3 
            - 50 – 100 cells/mm3 
            - <50 cells/mm3 
 
Baseline BMI (kg/m
2
) 
            - Normal (18.5 – 25) 
            - Underweight (<18.5 ) 
            - Overweight (>25) 
 
Virologic response (at 4 months) 
        Yes  
        No 
 
Employment status 
      Employed 
      Unemployed  
       
Initiating  ARV regimen  
     - 1a (3TC, efv, d4T/AZT) 
     - 1b (3TC, d4T, nvp) 
     - any first line incl lopinavir 
     - 2
nd
 line (ddI, AZT, LPV/r) 
     - other  
 
Year of initiation 
     2004/2005 
     2005/2006 
     2006/2007 
      
 
1 
1.37  (1.10 – 1.71)   0.006 
 
1.08  (1.02 - 1.15)   0.008 
 
0.92  (0.87 – 0.97)   0.001 
 
0.90  (0.89 – 0.92)   <0.001 
 
 
1 
1.53 (1.06 – 2.21)  0.022 
3.40 (2.56 - 4.52)  <0.001 
 
 
1 
2.18 (1.61 – 2.94)  <0.001 
0.88 (0.61 – 1.27 ) 0.493 
 
 
1 
2.81  (1.44 – 5.52)   0.003 
 
 
1 
1.10 (0.87 - 1.40) 0.422 
 
 
1 
1.08  (0.72 - 1.64)  0.704 
0.97 ( 0.53 – 1.79) 0.946 
0.92 (0.63 – 1.08) 0.156 
 
 
 
1 
1.42 (1.06 – 1.91) 0.020 
1.41 (1.04 – 1.92) 0.025 
 
 
1 
1.18 (0.93-1.49)  0.172 
 
1.09 (1.02 - 1.17)  0.007 
 
 
 
0.91  (0.89 – 0.92)   <0.001 
 
 
 23 
 
Despite an apparently strong association between gender and death in the univariate 
analysis, the effect of gender on hazard of death disappeared after adjusting for age and 
baseline CD4 count in the multivariate analysis. Age and baseline CD4 count remained 
statistically significant predictors of hazard of death in the adjusted model.  
 
2. Loss to follow up 
There were 6,617 subjects for analysis of loss-to-follow-up. Of these, 708 individuals 
were confirmed lost to follow up before the censor date 31
st
 October 2007: 243 of these 
were male and 465 were female. The Chi-square test for difference between two 
proportion showed no difference in the proportion of females lost to follow up compared 
to males (χ
2 
=0.1436  p = 0.705).These subjects contributed 11,849.9 person years of 
observation for analysis. Gender differences in rate of loss to follow up were estimated 
using Kaplan-Meier (KM) survival curves and incidence rates expressed per person-
years. The rate of loss to follow up of this cohort by gender, including a risk table 
demonstrating the numbers at risk for selected follow-up durations, is depicted in Figure 
3.  
 
The log-rank test for equality of survivor functions showed no evidence of a difference in 
the time to lost to follow up between females and males (χ
2 
=1.99 p = 0.1584). 
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time 0 6mo 1 yr 18mo 2 yr 2.5 yr 3 yr 
n at risk  
Male 
Female 
 
2229 
4388 
 
2213 
4355 
 
1723 
3497 
 
1197 
2616 
 
777 
1789 
 
468 
1105 
 
215 
474 
 
Figure 3: Kaplan-Meier plots for Loss to Follow-up for the Themba Lethu Clinical 
Cohort by gender 
 
Risk factors for loss to follow up were estimated using Cox proportional hazards models. 
Hazard ratios for each variable were calculated and are presented in Table 4 for both 
univariate and multivariate analyses. There was no difference in hazard of becoming lost 
to follow up between men and women in the univariate analysis. Age, baseline CD4 
count, baseline BMI and year of initiation on HAART were significantly associated with 
hazard of becoming lost to follow up in the univariate analysis. Those variables in the 
univariate analysis which changed the hazard ratio for gender by 10% or more were 
Male     
Female     
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entered into the multivariate analysis and retained at α=0.05.  The variables included in 
the final model were sex, age and baseline BMI category. Assumption testing for these 
models is presented in Appendix E. 
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Table 4: Factors associated with loss-to-follow-up after initiation of HAART 
 
 
Factor Univariate Model 
Hazard Ratio    ( CI )     p - value 
Multivariate Model 
Hazard Ratio    ( CI)      p - value 
Sex 
     Females 
     Males 
 
Age (years) 
Baseline weight (kgs) 
 
Baseline CD4 count (cells/mm
3
)  
Baseline CD4 count (cells/mm
3
) 
            - > 100 cells/mm3 
            - 50 – 100 cells/mm3 
            - <50 cells/mm3 
 
Baseline BMI (kg/m
2
) 
Baseline BMI (kg/m
2
) 
           - Normal (18.5 – 25) 
            - Underweight (<18.5 ) 
            - Overweight (>25) 
 
Employment status 
            Employed  
            Unemployed  
 
       
Initiating  ARV regimen  
     - 1a (3TC, efv, d4T/AZT) 
     - 1b (3TC, d4T, nvp) 
     - any first line incl lopinavir 
     - 2
nd
 line (ddI, AZT, LPV/r) 
     - other  
 
Year of initiation 
     2004/2005 
     2005/2006 
     2006/2007 
      
 
1 
1.12  (0.96 -1.31)   0.159 
 
0.98 (0.97 - 0.99)   <0.001 
1.00 (0.99 - 1.00)   0.764 
 
1.00  (1.00 - 1.00)   0.216 
 
1 
1.53 (1.06 – 2.21)  0.022 
3.40 (2.56 - 4.52)  <0.001 
             
            1.00 (0.98 -1.01) 0.841 
 
1 
1.51 (1.22 - 1.87)  <0.001 
1.38 (1.13 - 1.69) 0.002 
 
 
1 
1.15 (0.98 - 1.36) 0.086 
 
 
 
1 
0.86 (0.63 -1.17)  0.355 
1.47 (1.16 - 1.87) 0.002 
0.57 (0.33 - 0.98) 0.043 
1.20 (0.86 - 1.68) 0.283 
 
 
1 
1.61 (1.35 - 1.91) <0.001 
1.66 (1.30 - 2.11) <0.001 
 
 
1 
1.28 (1.05 - 1.55) 0.013 
 
0.98 (0.97 - 0.99)  0.002 
 
 
 
 
 
 
 
 
 
 
1 
1.44 (1.16 - 1.78) 0.001 
1.48  (1.21 - 1.82)  <0.001 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
The apparent lack of association between gender and loss to follow up in the univariate 
analysis was reversed after inclusion of the significant covariates age, baseline BMI and 
year of initiation on HAART. The hazard of becoming lost to follow up was 1.28 times 
greater for males when compared to females assuming age, baseline BMI and year of 
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initiation onto HAART were equal. However, interaction terms were investigated and 
there was significant interaction between sex and baseline BMI. The model was then 
stratified by baseline BMI and for those with normal baseline BMI, the hazard of 
becoming lost to follow up was 1.55 times greater for males when compared to females 
assuming age and year of initiation onto HAART were equal [HR = 1.55 (95% CI = 1.20 
- 2.00)]. There was no significant relationship between sex and hazard of becoming lost 
to follow up for those who were either underweight or overweight at baseline. 
 
Model fit and assumption testing was performed, and only the model for those with 
normal baseline BMI did not violate the assumption of proportional hazards and the 
model appeared to fit the data well. The models for those who were under- or overweight 
at baseline violated assumption testing and did not fit the data well. This apparent 
association between gender and hazard of loss to follow up observed in the multivariate 
analysis is likely to be a significant association only for those with individuals who 
initiate HAART with a normal baseline BMI. 
 
3. Death or Loss to follow up 
There were 6,617 subjects for loss-to-follow-up analysis and 1,021 individuals were 
confirmed dead or lost to follow up before the censor date 31
st
 October 2007. Of these, 
370 were male and 651 were female. The Chi-square test for difference between two 
proportion showed no difference in the proportion of females dead or lost to follow up 
compared to males (χ
2 
=3.52  p = 0.060).These subjects contributed  11,408.7 person 
years of observation for analysis. Gender differences in rate of death or loss to follow up 
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were estimated using Kaplan-Meier (KM) survival curves and incidence rates expressed 
per person-years. The rate of loss to follow up of this cohort by gender, including a risk 
table demonstrating the numbers at risk for selected follow-up durations, is depicted in 
Figure 4. 
 
 
 
 
 
 
Figure 4: Kaplan-Meier plots for Death or Loss to Follow-up for the Themba Lethu  
Clinical Cohort by gender 
 
time 0 6mo 1 yr 18mo 2 yr 2.5 yr 3 yr 
n at risk  
Male 
Female 
 
2229 
4388 
 
2133 
4233 
 
1631 
3364 
 
1123 
2510 
 
727 
1714 
 
435 
1056 
 
198 
451 
Male     
Female     
 29 
The log-rank test for equality of survivor functions showed that the time to death or loss 
to follow up of females was significantly greater than that of males (χ
2 
=8.61 p = 0.0033). 
 
Risk factors for death or loss to follow up were estimated using Cox proportional hazards 
models. Hazard ratios for each variable were calculated and are presented in Table 7 for 
both univariate and multivariate analyses. Men were 1.21 times more likely than women 
to die or become lost to follow up in the univariate analysis. Low baseline CD4 count 
(<50 cells/mm
3
) and abnormal baseline BMI were also significantly associated with 
hazard of death or loss to follow up. No variables in the univariate analysis changed the 
hazard ratio for gender by 10% or more. Variables in the univariate analysis with α=0.10 
were entered into the multivariate analysis and retained at α=0.05.  
Table 5: Factors associated with death or loss-to-follow-up after initiation of HAART 
 
Factor Univariate Model 
Hazard Ratio    ( CI )     p - value 
Multivariate Model 
Hazard Ratio    ( CI)      p - value 
Sex 
     Males  
     Females  
 
Age (in 5 year increments) 
Baseline weight (kgs) 
 
Baseline CD4 count (in 10 
cells/mm
3
 increments)  
 
Baseline CD4 count (cells/mm
3
) 
            - > 100 cells/mm3 
            - 50 – 100 cells/mm3 
            - <50 cells/mm3 
 
Baseline BMI (kg/m
2
) 
 
Baseline BMI (kg/m
2
) 
           - Normal (18.5 – 25) 
            - Underweight (<18.5 ) 
            - Overweight (>25) 
 
Employment status 
           Employed        
 
1 
1.21 (1.07 - 1.38) 0.003 
 
0.97 (0.93 - 1.01) 0.121 
           1.00 (0.99 -1.00) 0.153 
 
0.98 (0.97 - 0.98) <0.001 
 
 
1 
0.97 (0.81 - 1.16)  0.755 
1.45 (1.26 - 1.67) <0.001 
 
0.98 (0.97 - 0.99) 0.023 
 
 
1 
1.76 (1.48 - 2.10) <0.001 
1.23 (1.03 - 1.46)  0.023 
 
 
1 
1.13 (1.00 - 1.30) 0.059 
 
1 
1.22 (1.06 - 1.39)  0.004 
 
0.99 (0.95 - 1.03) 0.529 
 
 
0.98 (0.97 - 0.99) <0.001 
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           Unemployed 
            
Initiating  ARV regimen  
     - 1a (3TC, efv, d4T/AZT) 
     - 1b (3TC, d4T, nvp) 
     - any first line incl lopinavir 
     - 2
nd
 line (ddI, AZT, LPV/r) 
     - other  
 
Year of initiation 
     2004/2005 
     2005/2006 
     2006/2007 
      
 
 
1 
0.94 (0.74 - 1.22) 0.643 
1.26 (1.02 - 1.55) 0.035 
0.72 (0.48 - 1.07) 0.107 
1.05 (0.79 - 1.41) 0.723 
 
 
1 
1.56 (1.34 - 1.81) <0.001 
1.61 (1.33 -1.94) <0.001 
 
 
 
 
 
 
 
 
 
1 
1.53 (1.30 - 1.79)  <0.001 
1.57  (1.28 - 1.90) <0.001 
 
 
In the multivariate analysis, the hazard of death or lost to follow up was 1.22 times 
greater for men when compared to women after adjusting for baseline CD4 count, age 
and year of initiation on HAART. Age and baseline CD4 count did not independently 
have an effect on the hazard of death or loss to follow up. Gender was the only covariate 
which did not violate the assumption of proportional hazards. Thus the most 
parsimonious model included only gender. Interaction terms were tested for but no 
significant interactions were found. Assumption testing for these models is presented in 
Appendix E.  
 
CD4 cell count Response 
6,326 participants had CD4 counts for analysis. 202 of these participants did not have 
baseline CD4 counts and were excluded form further analysis. This left 6,124 subjects for 
further analysis. The mean baseline CD4 count amongst these individuals was 90 
cells/mm
3
 (± 67 cells/mm
3
). The question of interest was whether there was any 
difference in CD4 cell count responses between men and women. Two time periods were 
considered – CD4 cell count response four months after initiation of HAART and ten 
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months after initiation of HAART. The time to 100 cell increase in CD4 count was also 
estimated and all three analyses are presented below. 
 
Women had higher baseline CD4 count than males and the gender difference between the 
mean CD4 count at four and ten months after HAART initiation increased even further. 
This is shown in Figure 5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Mean CD4 count at selected intervals after initiation on HAART by 
gender 
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4,567 individuals (75% of the cohort included in this analysis) had CD4 cell counts 
recorded at four months after initiation of HAART. The mean overall CD4 count at four 
months was 224.8 cells/mm
3
 (± 128 cells/mm
3
). The following outcomes were 
investigated: any increase in CD4 count by four months, a 100 cell increase in CD4 count 
response by four months and a 50% increase in CD4 count by four months. Differences 
between the genders are presented in Table 6 below. 
 
Table 6: CD4 cell count responses four months after Initiation of HAART by 
gender  
 
 Overall (n) 
 
N (%) OR (95% CI) 
Frequency N (%) 
              - males 
               -females 
4567 (100)  
1513 (33.1) 
3054 (66.9) 
 
Any CD4 count 
response - males 
               -females 
4117 (93.6) 
 
 
1368 (93.1) 
2749 (93.9) 
 
1 
1.07 (0.97 – 1.19) 
100 cell increase  
              - males 
               -females 
2399 (54.6)  
719 (48.9) 
1680 (57.4) 
 
1 
1.32  (1.18 – 1.46) 
50% increase CD4 cell                 
              - males 
               -females 
3452 (78.9)  
1146 (78.2) 
2306 (79.1) 
 
1 
1.06  (0.96 – 1.17) 
 
Women had no significant advantage over men in terms of any positive CD4 count 
response at four months after adjusting for age and baseline CD4 count. However, 
women were 35% more likely to achieve a 100 cell increase in CD4 count [OR =1.35 
(95% CI = 1.19 -1.54)] and 33% more likely to achieve a 50% increase in CD4 count 
[OR 1.33 (95% CI 1.11 – 1.59)] after four months of HAART when compared to men 
[OR = 1.14 (95% CI = 1.03 – 1.27)]. These odds ratios were adjusted for age and baseline 
CD4 count. Interaction terms were tested for but no significant interactions were found. 
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CD4 cell response at ten months after HAART initiation 
3,594 individuals (59% of the cohort included in this analysis) had CD4 cell counts 
recorded at ten months after initiation of HAART. The proportion of men and women 
with CD4 counts recorded at 10 months is almost identical to the baseline gender 
distribution of the overall cohort. The overall mean CD4 count at ten months was 276 
cells/mm
3
 (± 140.5 cells/mm
3
). The following three outcomes were again investigated: 
any increase in CD4 count by ten months, a 100 cell increase in CD4 count response by 
ten months and a 50% increase in CD4 count by ten months after initiation on HAART. 
Differences between the genders are presented in Table 9 below. 
 
Table 7: CD4 cell count responses ten months after Initiation of HAART by gender  
 
 Overall 
n=3594 
Males 
n= 1183 (33%) 
Females 
n=2411 (67%) 
χ2 (p value)/ z 
score (p value) 
Any CD4 count 
response - N (%) 
               - x , std 
 
3454 (95.5) 
177.4 (127.8) 
 
1083 (94.5) 
156.3 (111.9) 
 
2215 (96.0) 
187.9 (133.8) 
  
3.826 (0.050) 
-6.898 (<0.0001) 
100 cell increase  
               - N (%) 
 
2543 (73.6) 
 
795 (69.4) 
 
1748 (75.7) 
 
15.975 (<0.001) 
50% increase CD4 cell                 
               - N (%) 
 
2948 (85.8) 
 
960 (84.2) 
 
1988 (86.6) 
 
3.526 (0.060) 
 
Women had significant advantages over men in terms of CD4 count response at ten 
months in all categories after adjusting for age and baseline CD4 count. Women were 
42% more likely to achieve a 100 cell increase in CD4 count [OR =1.42 (95% CI = 1.20 -
1.68)], 55% more likely to achieve a 50% increase in CD4 count [OR 1.55 (95% CI 1.22 
– 1.97)] and 73% more likely to show any CD4 response at ten months after initiation on 
HAART when compared to men [OR = 1.73 (95% CI = 1.19 – 2.52)]. These odds ratios 
 34 
were adjusted for age and baseline CD4 count. Interaction terms were tested for but no 
significant interactions were found. 
 
Time to 100 cell increase in CD4 count 
Survival analysis was conducted using a 100 cell increase in CD4 count as the endpoint. 
Of the 6,617 individuals in the cohort, 290 did not have more than one CD4 count 
available and so were excluded from this stage of the analysis. Of the remaining 6,327 
individuals, 3,905 (62%) achieved this endpoint before the censor date 31 October 2007. 
Of these, 1,208 (34.1%) were men and the remaining 2,697 (65.9%) were women. The 
proportion of females who achieved a 100 cell increase in CD4 count was significantly 
greater than the proportion of males who did so (χ
2 
=44.81  p = <0.001). These subjects 
contributed 2,293,779 person days of observation for analysis. Gender differences in time 
to achieving a 100 cell increase in CD4 count were estimated using Kaplan-Meier (KM) 
survival curves and are depicted in Figure 6. 
 
 
 
 
 
 
 
 
 
Male     
Female     
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Figure 6: Kaplan-Meier plots for time to achieving a 100 cell increase in CD4 count by  
gender 
 
The log-rank test for equality of survivor functions showed that women achieved a 100 
cell increase in CD4 count significantly sooner than their male counterparts (χ2
 
= 40.83   
p= <0.0001). The median time to achieving this endpoint was 275 days for women and 
299.5 days for men. 
Factors associated with achieving a 100 cell increase in CD4 count were estimated using 
Cox proportional hazard models. Hazard ratios for each variable of interest were 
calculated and are presented in Table 8 for both univariate and multivariate analyses. No 
variables in the univariate analysis changed the hazard ratio for gender by 10% or more. 
Variables in the univariate analysis with α=0.20 were entered into the multivariate 
analysis and retained at α=0.05.   
time 0 6mo 1 yr 18mo 2 yr 2.5 yr 3 yr 
n at risk  
Male 
Female 
 
2156 
4171 
 
1439 
2498 
 
839 
1460 
 
512 
860 
 
309 
517 
 
179 
279 
 
59 
89 
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Table 8: Factors associated with a 100 cell increase in CD4 count after initiation of 
HAART 
 
Factor Univariate Model 
Hazard Ratio    ( CI )     p - value 
Multivariate Model 
Hazard Ratio    ( CI)      p - value 
Sex 
     Males  
     Females  
 
Age (years) 
Baseline weight (kgs) 
 
Baseline CD4 count (cells/mm
3
)  
Baseline CD4 count (cells/mm
3
) 
            - > 100 cells/mm3 
            - 50 – 100 cells/mm3 
            - <50 cells/mm3 
 
Baseline BMI (kg/m
2
) 
Baseline BMI (kg/m
2
) 
           - Normal (18.5 – 25) 
            - Underweight (<18.5 ) 
            - Overweight (>25) 
 
Employment status 
            Unemployed 
            Employed 
 
Initiating HAART regimen 
     - 1a (3TC, efv, d4T/AZT) 
     - 1b (3TC, d4T, nvp) 
     - any first line incl lopinavir 
     - 2
nd
 line (ddI, AZT, LPV/r) 
     - other  
 
Year of initiation 
     2004/2005 
     2005/2006 
     2006/2007     
 
1 
1.25 (1.16 - 1.33) <0.001 
 
0.99 (0.98 - 0.99)  <0.001 
1.00 (0.99 - 1.00) 0.784 
 
1.00 (0.99 - 1.00) 0.242 
 
1 
1.04 (0.96 - 1.13) 0.335 
0.93 (0.87 - 1.00) 0.061 
 
1.00 (0.99 - 1.01)  0.065 
 
1 
0.80 (0.73 - 0.88) <0.001 
0.98 (0.90 - 1.06)  0.623 
 
 
1 
1.08 (1.01 - 1.15) 0.020 
 
 
1 
1.07 (0.95 - 1.22) 0.252 
0.86 (0.76 – 0.97) 0.013 
1.06 (0.89 - 1.26) 0.493 
1.05 (0.91 – 1.23) 0.477 
 
 
1 
0.91 (0.85 - 0.98) 0.024 
0.82 (0.76 - 0.89) <0.001 
 
1 
1.21 (1.13 - 1.29) <0.001 
 
0.99 (0.98 - 0.99)  <0.001 
 
 
1.00 (0.99 - 1.00)  0.937 
 
 
 
 
 
 
 
 
 
 
 
 
1 
1.13 (1.05 - 1.20)  0.001 
 
 
 
 
 
 
 
 
 
1 
0.86 (0.79 - 0.93) <0.001 
0.78 (0.72 - 0.84) <0.001 
 
The hazard ratio for achieving a 100 cell increase in CD4 count was 21% greater for 
women when compared to men after adjusting for baseline CD4 count, age, employment 
status and year of initiation on HAART. Baseline CD4 count did not independently affect 
the hazard of achieving a 100 cell increase in CD4 count. Gender was the only covariate 
which did not violate the assumption of proportional hazards. Thus the final most 
parsimonious model included only gender. The variables included in the final model were 
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sex, age, baseline CD4 count and year of enrollment into the programme. Interaction terms were 
tested for but no significant interactions were found. Assumption testing for these models is 
presented at the end of the chapter. 
 
Virologic Response 
4,356 participants had HIV RNA viral load records for analysis. 34% (n= 1,480) of these 
people were male and the remaining 66% (n= 2,876) were female. This was almost 
identical to the gender distribution of the overall cohort. Virologic response was defined 
as a reduction of HIV viral load to less than 400 copies/ml. The objective was to 
determine if there were any gender differences in the odds of suppressing HIV viral load 
at two time periods - four months after initiation of HAART and ten months after 
initiation of HAART. The time to first ever HIV viral load suppression was also 
estimated and all three analyses are presented below. 
 
HIV viral load suppression at four months after HAART initiation 
3,441 individuals (79% of the cohort included in this analysis) had HIV viral loads 
recorded at four months after initiation of HAART. 1,178 (34.23%) of these participants 
were men and 2,263 (65.8%) were women. There was no significant differences in the 
proportion of women achieving virologic suppression at four months after initiating 
HAART when compared to men (χ2 = 0.3834 p=0.536).  Factors associated with 
suppression of HIV viral load at four months after initiation of HAART were investigated 
using logistic regression. Odds ratios were calculated and are presented in Table 9 for 
both univariate and multivariate analyses.  
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Table 9: Factors associated with suppression of HIV viral load four months after 
initiation of HAART 
 
Factor Univariate Model 
Odds Ratio    ( CI )     p - value 
Multivariate Model 
Odds Ratio    ( CI)      p - value 
Sex 
     Males  
     Females  
 
Age (years) 
Baseline weight (kgs) 
 
Baseline CD4 count (cells/mm
3
)  
Baseline CD4 count (cells/mm
3
) 
            - > 100 cells/mm3 
            - 50 – 100 cells/mm3 
            - <50 cells/mm3 
 
Baseline BMI (kg/m
2
) 
Baseline BMI (kg/m
2
) 
           - Normal (18.5 – 25) 
            - Underweight (<18.5 ) 
            - Overweight (>25) 
 
Employment status 
            Unemployed 
            Employed 
 
Initiating HAART regimen 
     - 1a (3TC, efv, d4T/AZT) 
     - 1b (3TC, d4T, nvp) 
     - any first line incl lopinavir 
     - 2
nd
 line (ddI, AZT, LPV/r) 
     - other  
 
Year of initiation 
     2004/2005 
     2005/2006 
     2006/2007  
 
1 
1.08 ( 0.85 – 1.37) 0.536 
 
1.00 (0.99 – 1.01) 0.894 
1.01 (0.99 – 1.02) 0.307 
 
1.00 (0.99 – 1.00) 0.143 
 
1 
0.90 (0.66 – 1.31) 0.668 
1.13 ( 0.81 – 1.57) 0.481 
 
1.02 (0.99 – 1.05) 0.255 
 
1 
0.93 ( 0.66 – 1.31) 0.668 
1.13 ( 0.81 – 1.57) 0.481 
 
 
1 
1.25 (0.98 – 1.58) 0.077 
 
 
1 
0.88 (0.57 – 1.36) 0.571 
1.20 (0.76 – 1.89) 0.437 
1.26 (0.65 – 2.43) 0.494 
1.33 (0.73 – 2.42) 0.358 
 
 
1 
0.85 (0.61 – 1.18) 0.337 
0.89 (0.65 – 1.22) 0.472 
 
1 
1.07 (0.83 – 1.37) 0.621 
 
1.00 (0.98 – 1.01) 0.793 
 
 
1.00 (1.00 – 1.00) 0.156 
 
 
No significant association between gender and virologic response at four months after 
initiation of HAART was found in the univariate analysis. None of the other cofactors or 
covariates significantly predicted virologic response at four months after initiation of 
HAART in the univariate analysis either. Those variables in the univariate analysis which 
changed the odds ratio for gender by 10% or more were entered into the multivariate 
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analysis and retained at α=0.05.  After adjusting for age and CD4 count in the 
multivariate analysis there was still no association between gender and virologic response 
at four months.  
 
HIV viral load suppression at ten months after HAART initiation 
2,900 individuals (67% of the cohort included in this analysis) had HIV viral loads 
recorded at ten months after initiation of HAART. 979 (33.8%) of these participants were 
men and 1,921 (66.2%) were women.  The proportion of women achieving virologic 
suppression at ten months after initiating HAART was significantly greater than the 
proportion of males who did so (χ2 = 10.1560 p=0.001).  Factors associated with 
suppression of HIV viral load at ten months after initiation of HAART were investigated 
using logistic regression. Odds ratios were calculated and are presented in Table 10 for 
both univariate and multivariate analyses. Those variables in the univariate analysis 
which changed the odds ratio of virologic suppression for gender by 10% or more were 
entered into the multivariate analysis and retained at α=0.05.   
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Table 10: Factors associated with suppression of HIV viral load ten months after 
initiation of HAART 
 
Factor Univariate Model 
Hazard Ratio    ( CI )     p - value 
Multivariate Model 
Hazard Ratio    ( CI)      p - value 
Sex 
     Males  
     Females  
 
Age (years) 
Baseline weight (kgs) 
 
Baseline CD4 count (cells/mm
3
)  
Baseline CD4 count (cells/mm
3
) 
            - > 100 cells/mm3 
            - 50 – 100 cells/mm3 
            - <50 cells/mm3 
 
Baseline BMI (kg/m
2
) 
Baseline BMI (kg/m
2
) 
           - Normal (18.5 – 25) 
            - Underweight (<18.5 ) 
            - Overweight (>25) 
 
Employment status 
            Unemployed 
            Employed 
 
Initiating HAART regimen 
     - 1a (3TC, efv, d4T/AZT) 
     - 1b (3TC, d4T, nvp) 
     - any first line incl lopinavir 
     - 2
nd
 line (ddI, AZT, LPV/r) 
     - other  
 
Year of initiation 
     2004/2005 
     2005/2006 
     2006/2007 
      
 
1 
1.45 (1.15 – 1.83) 0.002 
 
1.01 (1.00 – 1.02) 0.216 
0.99 (0.98 – 1.00) 0.102 
 
1.00 (1.00 – 1.00) 0.300 
 
1 
1.03 (0.75 – 1.41) 0.875 
0.81 (0.62 – 1.04) 0.103 
 
0.99 (0.97 – 1.02) 0.708 
 
1 
1.20 (0.83 – 1.74) 
0.99 (0.73 – 1.35) 0.981 
 
 
1 
1.26 (0.99 – 1.60) 0.062 
 
 
1 
0.79 (0.51 – 1.21) 0.277 
0.85 (0.52 – 1.16) 0.221 
0.87 (0.49 – 1.55) 0.638 
0.97 (0.56 – 1.68) 0.905 
 
 
1 
0.94 (0.70 – 1.25) 0.661 
1.14 (0.84 – 1.54) 0.390 
 
1 
1.54 (1.21 – 1.97) <0.001 
 
1.01 (0.99 – 1.03 ) 0.111 
 
 
1.00 (1.00 – 1.00) 0.530 
 
 
Gender significantly predicted virologic response at ten months after initiation on 
HAART in the univariate analysis. No other factor or covariate was significantly 
associated with risk of HIV viral load suppression at ten months in the univariate 
analysis. In the multivariate analysis women were 54% more likely to achieve HIV viral 
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load suppression after adjusting for CD4 count and age [OR =1.54 (95% CI =1.21-1.97)]. 
Neither age nor baseline CD4 count added significance to the model and the most 
parsimonious model included only gender. Interaction terms were tested for but no 
significant interactions were found. 
 
Time to first ever HIV viral load suppression 
Gender differences in time to first ever HIV viral load suppression were investigated. Of 
the 6,617 individuals in the cohort, 5,109 individuals had viral load dates and values 
recorded and were included in the survival analysis. Of these, 4,684 (92%) achieved this 
endpoint (HIV viral load suppression) before the censor date 31 October 2007. 1,532 
(32.7%) were men and the remaining 3,152 (67.3%) were women. The proportion of 
females who achieved virologic suppression was significantly greater than the proportion 
of males who did so (χ
2 
=5.15  p = 0.023). These subjects contributed 1,198,838 person 
days of observation for analysis. Gender differences in time to achieving HIV viral load 
suppression were estimated using Kaplan-Meier (KM) survival curves and are depicted in 
Figure 7 along with a risk table demonstrating the numbers at risk for selected follow-up 
durations,. 
 
The log-rank test for equality of survivor functions confirmed that there were no 
significant differences in time to first virologic suppression between men and women 
(χ2=0.02   p= 0.8904). The median time to achieving this endpoint was 142 days for 
women and 141 days for men. 
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Figure 7:  Kaplan-Meier plots for time to first ever suppression of HIV viral load by 
gender 
 
Factors associated with achieving first ever virologic response were estimated using Cox 
proportional hazard models. Hazard ratios for each variable of interest were calculated 
and are presented in Table 11 for both univariate and multivariate analyses. In the 
univariate analysis, there was no difference between men and women in terms of the 
likelihood of suppressing HIV viral load after initiation of HAART. Those who were 
employed were more likely to achieve virologic suppression at four months. No variables 
in the univariate analysis changed the hazard ratio for the relationship between gender 
time 0 6mo 1 yr 18mo 2 yr 2.5 yr 3 yr 
n at risk  
Male 
Female 
 
1694 
3415 
 
618 
1309 
 
295 
603 
 
139 
202 
 
64 
146 
 
31 
62 
 
11 
19 
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and hazard of virologic suppression at four months by 10% or more but age, baseline 
CD4 count and year of initiation on treatment were included in the multivariate analysis 
as they were believed to be important potential confounders.   
 
Table 11: Factors associated with first ever HIV viral load suppression after initiation 
of HAART 
 
Factor Univariate Model 
Hazard Ratio    ( CI )     p - value 
Multivariate Model 
Hazard Ratio    ( CI)      p - value 
Sex 
     Males  
     Females  
 
Age (years) 
Baseline weight (kgs) 
 
Baseline CD4 count (cells/mm
3
)  
Baseline CD4 count (cells/mm
3
) 
            - > 100 cells/mm3 
            - 50 – 100 cells/mm3 
            - <50 cells/mm3 
 
Baseline BMI (kg/m
2
) 
Baseline BMI (kg/m
2
) 
           - Normal (18.5 – 25) 
            - Underweight (<18.5 ) 
            - Overweight (>25) 
 
Employment status 
            Unemployed 
            Employed 
 
Initiating HAART regimen 
     - 1a (3TC, efv, d4T/AZT) 
     - 1b (3TC, d4T, nvp) 
     - any first line incl lopinavir 
     - 2
nd
 line (ddI, AZT, LPV/r) 
     - other  
 
Year of initiation 
     2004/2005 
     2005/2006 
     2006/2007 
      
 
1 
1.00 (0.94 – 1.07) 0.891 
 
1.00 (1.00 – 1.00) 0.887 
1.00 (1.00 – 1.00) 0.525 
 
1.00 (1.00 – 1.00) 0.815 
 
 
 
 
 
1.00 (1.00 – 1.00) 0.426 
 
1 
1.00 (0.92 – 1.10) 0.924 
1.06 (0.98 – 1.14) 0.172 
 
 
1 
1.14 (1.07 – 1.21) <0.001 
 
 
1 
0.88 (0.79 – 0.99) 0.036 
1.00 (0.89 – 1.11) 0.935 
1.11 (0.95 – 1.29) 0.203 
0.98 (0.86 – 1.13) 0.203 
 
 
1 
1.28 (1.19 – 1.38) <0.001 
1.62 (1.51 – 1.75) <0.001 
 
1 
1.03 (0.97 – 1.10) 0.313 
 
1.00 (0.99 – 1.01) 0.277 
 
 
1.00 (1.00 – 1.00) 0.851 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 
1.29 (1.19 – 1.39) <0.001 
1.66 (1.53 – 1.79) <0.001 
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The hazard ratio for achieving first ever HIV viral load suppression was not significantly 
different between the genders after adjusting for baseline CD4 count, age and year of 
initiation on HAART. Neither baseline CD4 count nor age independently affected the 
hazard of achieving first ever HIV viral load suppression. Gender was the only covariate 
which did not violate the assumption of proportional hazards. Thus the most 
parsimonious model included only gender. Interaction terms were tested for but no 
significant interactions were found. Assumption testing for these models is presented in 
Appendix E. 
 
Weight Gain 
5001 participants had baseline weight values for analysis. 1696 (33.9%) of these 
individuals were men and the remaining 3305 (66.1%) were women. This was similar to 
the gender distribution of the overall cohort. The mean baseline weight amongst these 
people was 60.1 kg (± 13.3 kg) and mean baseline BMI was 22.5 kg/m
2
 (± 5.0 kg/m
2
). 
Initially there appeared to be no significant differences between the baseline weight of 
these participants, but after stratifying by BMI, evidence of a significant difference in 
both baseline weight and baseline BMI emerged. Predictably, men weighed more at 
baseline (p=<0.0001) and women had a higher mean BMI than men at baseline 
(p=<0.0001). This apparent difference was consistent for both categories of BMI – 
overweight (BMI>25) and normal or underweight (BMI<=25). Only those with a low or 
normal BMI at baseline were considered in the remaining analysis as a gain in weight for 
persons with a high baseline BMI is probably not a sign of clinical improvement on 
HAART.  
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Weight gain four months after HAART initiation 
Amongst those with normal or low BMI at baseline, the mean weight at four months was 
62.5 kg (± 9.0 kg) for men and 57.1 kg (± 8.7kg) for women. This was significantly 
different (p <0.0001).  The following weight outcomes were investigated: any increase in 
weight by four months, a five kg increase in weight by four months and a 5% increase in 
weight by four months. Differences between the genders are presented in Table 12 below. 
 
Table 12: Weight gain four months after initiation of HAART by gender  
 
 Overall 
 
Males 
 
Females 
 
χ2 (p value)/ z 
score (p value) 
Weight gain (kg) ( x , std) 3.75 (5.9) 3.72 (6.0) 3.76 (5.8)  -0.206 (0.8365) 
5 kg increase (n, %) 1141 (39.2) 438 (37.8) 703 (40.2) 1.5801 (0.209) 
5% weight increase  (n, %) 1585 (54.5) 607 (52.4) 978 (55.99) 3.3181 (0.069) 
 
There was no evidence to suggest that the mean weight gain at four months was different 
comparing men and women. There were also no significant differences in the proportion 
of women who gained five kilograms or who increased their weight by five percent from 
baseline weight after four months on HAART when compared to men. 
 
Factors associated with any weight gain four months after initiation on HAART were 
investigated with univariate and multivariate logistic regression models. Odds ratios for 
the relationship between weight gain at four months after HAART initiation and each 
variable of interest were calculated and are presented in Table 15. In the univariate 
analysis, women were 1.17 times more likely to gain
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of HAART. Other significant predictors of weight gain included baseline CD4 count, 
baseline BMI and year of initiation on HAART.  
 
Variables in the univariate analysis which altered the odds ratio for the relationship 
between sex and weight gain at four months after HAART initiation by 10% or more 
were entered into the multivariate analysis and retained at α=0.05.  Factors included in 
the multivariate analysis were gender, baseline CD4 count and baseline BMI.  
 
Table 13: Factors associated with weight gain four months after initiation of HAART 
 
Factor Univariate Model 
Odds Ratio    ( CI )     p - value 
Multivariate Model 
Odds Ratio    ( CI)      p - value 
Sex 
     Males  
     Females  
 
Age (years) 
Baseline weight (kgs) 
 
Baseline CD4 count (cells/mm
3
)  
Baseline CD4 count (cells/mm
3
) 
            - > 100 cells/mm3 
            - 50 – 100 cells/mm3 
            - <50 cells/mm3 
 
Baseline BMI (kg/m
2
) 
Baseline BMI (kg/m
2
) 
           - Normal (18.5 – 25) 
            - Underweight (<18.5 ) 
            - Overweight (>25) 
 
Employment status 
            Unemployed 
            Employed 
 
Initiating HAART regimen 
     Regimen 1a  
     Regimen 1b  
     Regimen 2 
     Other 
 
Year of initiation 
     2004/2005 
     2005/2006 
     2006/2007     
 
1 
1.17 (1.01 - 1.35) 0.034 
 
1.00 (0.99 - 1.01) 0.151 
0.97 (0.96 - 0.97) <0.001 
 
0.99 (0.99 - 0.99) <0.001 
 
1 
1.46 (1.21 - 1.74) <0.001 
2.10 (1.77 - 2.48) <0.001 
 
0.91 (0.89 - 0.92) <0.001 
 
1 
2.37 (1.88 - 2.97) <0.001 
0.52 (0.44 - 0.60) <0.001 
 
 
1 
1.09 (0.95 - 1.26) 0.218 
 
 
1 
0.49 (0.68 - 1.17) 0.411 
1.00 (0.69 - 1.44) 0.997 
0.94 (0.80 - 1.10) 0.449 
 
 
1 
1.21 (1.02 - 1.43) 0.025 
1.64 (1.38 - 1.95) <0.001 
 
1 
1.26 (1.07 - 1.49) 0.007 
 
1.01 (1.00 - 1.01) 0.026 
 
 
 
 
1 
1.35 (1.12 - 1.63) 0.002 
1.82 (1.53 - 2.16) <0.001) 
 
0.91 (0.89 -0.92) <0.001 
 
1 
2.14 (1.68 - 2.70) <0.001 
0.52 (0.44 - 0.61) <0.001 
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Women were 26% more likely to have gained weight four months after initiation on 
HAART than their male counterparts after adjusting for age, baseline CD4 count and 
baseline BMI. Interaction terms were investigated and no significant interaction was 
found.
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CHAPTER FOUR: DISCUSSION 
 
The aim of this study was to determine and describe gender differences in clinical and 
immunological outcomes in a population of HIV infected South African adults. The 
results showed that women had advantages over their male counterparts in terms of both 
clinical and immunological outcomes. The risk of death and/or loss to follow up was 
greater for men when compared to women. Women were also significantly more likely to 
show an increase in CD4 counts, more likely to suppress HIV viral load (at ten months 
after initiation) and to gain weight after initiation on HAART.  
 
Baseline Characteristics 
The baseline characteristics of this cohort of HIV-infected individuals differed from the 
populations studied in previous research. There were a significantly greater proportion of 
women in this cohort compared to other European [16] and North American cohorts [8] 
which consisted largely of males. At baseline, the women in this cohort were more likely 
to be initiated on Regimen 1B (lamivudine, stavudine and nevirapine) or a regimen with a 
lopinavir/ritonavir substitution. This is largely explained by the fact that these drugs are 
preferred to efavirenz (part of the traditional regimen 1A) in women who are pregnant or 
planning to fall pregnant. Efavirenz is considered potentially teratogenic and concerns 
have been raised regarding the potential for neural tube defects in the unborn child if used 
in the first trimester [31]. The initiating HAART regimen did not appear to have any 
significant effect on any of the clinical or immunological outcomes analysed and this 
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baseline difference was thus unlikely to have been a confounding factor in the 
associations observed between gender and the outcomes of interest. 
 
Several individuals in this cohort were recorded as being initiated on second line 
treatment despite being treatment-naïve at the time of initiation. This is an unlikely 
scenario and presumably these observations constitute either errors in the regimen dataset 
or the individuals were not naïve on entry into the cohort. As this is anonymised data, it 
was impossible to check the accuracy of these records. It is unlikely that these 
misclassification errors occurred in a non-random fashion and, as such, probably did not 
bias the outcome. To check the possibility of these errors influencing the results, those 
with a second line initiating regimen were excluded and the analysis repeated. The results 
were unchanged. 
 
The gender distribution in this cohort is changing over time. Initially, there was more 
than double the number of females accessing treatment on this programme compared to 
males, but over time the rates of male enrollment has been increasing. Currently, women 
still outnumber the men, but by a much smaller margin. It is unlikely that this change can 
be attributed to a corresponding increase in incidence of new male HIV infections as the 
South African national HIV statistics do not suggest this [32]. This change may be due to 
changing perceptions and improved trust in the antiretroviral rollout programme.  
 
One of the important reasons for fewer males accessing the treatment programme may be 
financial constraints. The services and treatment at the Themba Lethu Clinic is offered 
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free of charge but patients still need transport money to get to the clinic, which is often 
far from their homes or place of work. Additionally, the men were significantly more 
likely to be employed than the women in this cohort and difficulties getting time off work 
for regular clinic visits or loss of income due to days of work missed may prevent more 
men from accessing treatment. A visit to the clinic often involves a significant part of the 
day spent in queues although the recent addition of electronic live-capture of clinical data 
using TherapyEdge-HIV
TM
 during these clinical visits may be improving queue 
efficiency and speed of treatment collection. This may result in reduced waiting time and 
mean less time off work.  
 
Death and Loss to Follow-up 
The findings suggested there were little differences in survival for women after initiating 
HAART when considering the confirmed deaths only. However we can assume that a 
certain proportion of those lost to follow up are dead and previous work investigating 
causes for lost to follow up at the Themba Lethu Clinic showed that at least 27% of those 
individuals confirmed lost to follow up were actually dead [27]. When considering those 
confirmed dead or lost to follow up in this analysis, men were at a significant 
disadvantage even after adjusting for the potential confounders CD4 count and age.   
 
Any difference in hazard of death alone between the genders was explained by the 
significantly lower baseline CD4 counts with which men presented. Previous research has 
suggested gender-specific normal ranges for CD4 counts in HIV-infected [11] and HIV 
uninfected individuals [28] and other studies have consistently reported women have 
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higher CD4 counts at time of seroconversion as well as maintaining slightly higher CD4 
counts than men during the course of infection [19].  Treating CD4 counts as continuous 
variables may result in possible residual confounding after adjusting for baseline CD4 
count if gender –specific normal ranges are in fact present. However, there is a lack of 
information regarding this normal “range” during HAART treated HIV infection and this 
may be a difficult to control for.  
 
CD4 count response 
The women in this study showed not only higher CD4 counts at baseline but also 
significantly greater CD4 count responses after initiating HAART. Women were more 
likely to have a 100 cell increase in CD4 count and were more likely to have increased 
their CD4 counts by 50% than the men. This finding was consistent at four months and 
ten months after initiating HAART. If the difference in baseline CD4 count is due to 
differences in gender-specific “normal ranges” for CD4 lymphocytes, then it may suggest 
that women should be started on antiretroviral therapy at higher CD4 counts than men. 
Alternatively, the baseline difference in CD4 counts may suggest that gender differences 
in help-seeking behaviour exist, with men seeking treatment later than women. This has 
certainly been the case in other African countries and advanced HIV disease at time of 
initiating HAART significantly contributed to mortality [6, 26]. Although not 
demonstrated in this study, if males are presenting later to treatment programmes, they 
are likely to receive limited benefits from HAART and suffer increased mortality even 
once receiving HAART.   
 
 52 
Virologic suppression 
Suppression of HIV viral load at ten months after initiating HAART was also more likely 
to occur in women than men. This is consistent with other findings [35, 36]. No short 
term advantages in suppression of viral load (after four months of HAART) were 
demonstrated for either gender in this cohort and this may suggest that if men can stay in 
treatment programmes and be adherent on treatment for long enough, the survival 
advantage demonstrated by women may disappear.  
 
Weight Gain 
Loss of less than ten percent of presumed or measured body weight is one of the WHO 
stage 2 criteria [29]. This single measure may be too simplistic as loss or gain of a certain 
percentage weight depends on the starting weight as well as the individual’s body 
composition. Indeed there were no significant differences in baseline weight between 
men and women but the women presented with a higher mean baseline BMI. This 
suggests that the men in this study had lost more weight by the time that they presented 
for treatment when compared to the women. While body mass index (BMI) has been 
used by WHO as the standard for anthropometric statistics since the 1980s [30], its’ use 
has limitations too, notably not accounting for distribution of muscle and bone mass. As 
such, BMI may not be an appropriate tool for assessing body composition and health 
across different populations. In the HIV infected population this may certainly be the case 
as individuals may suffer severe muscle depletion as part of the HIV wasting syndrome 
while others may have abnormal adipose tissue distribution due to antiretroviral toxicity. 
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Limitations 
In considering the findings of this study, it is important to consider the following 
limitations. Selection bias may have arisen as only those who present for treatment were 
available for analysis. If there is a systematic difference between men and women in 
terms of help-seeking behaviour (which is suggested by the greater proportion of women 
accessing treatment and the earlier stage at which women present) then the results may be 
biased. As with all cohorts, high rates of loss to follow up can significantly bias the 
results if those who are lost to follow up are significantly different from those who 
remain in the study in terms of the exposure or outcome of interest. There was no 
evidence to suggest that there were any differences in gender distribution between those 
who were lost to follow up and those who remained in the study.   
 
While a great amount of effort and care is put into collecting and capturing data on the 
Themba Lethu Clinical Cohort, the accuracy of the collected data could not be checked 
against any source due to the de-identified nature of the data. In particular, the accuracy 
of the death data is largely dependant on verbal reports from family members of the 
deceased and the inability to cross-reference this data with a national death register 
makes ascertainment of accurate death dates difficult. Additionally, if mortality is 
significantly higher for men than women as suggested in this project, then cause of death 
needs to be investigated for gender bias. Diseases such as Kaposi’s sarcoma, which 
occurs fairly early in HIV infection, tends to occur more commonly in men [23] and 
could result in significantly earlier mortality for males. This information was not 
available to the researcher. 
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The clinical and immunological outcomes in this study were only considered up to 10 
months after initiation of HAART in most of the analysis and it is possible that the 
advantages suggested by the data for women may not be significant or even possibly 
reversed should longer time periods on treatment be considered. Indeed as HIV-infected 
individuals are treated with antiretroviral therapy for longer periods, more research is 
needed to determine if gender differences in clinical and immunological outcomes persist 
on long-term therapy. Certainly there is evidence for female predominance in long-term 
toxicity on antiretrovirals such as lactic acidosis [33, 34] with the risk of lactic acidosis 
estimated to be 2.5 times greater for women than men [34]. 
 
This analysis used survival methods which considered achievement of defined outcomes 
in a time to first event manner. As such, recurrent events were not considered nor were 
such events accounted for. If women were more likely to relapse after achieving a 
particular end point, this would certainly lessen the impact of finding any difference 
between the genders in time to achieving the end point.  
 
The violation of the assumptions and poor model fit in the lost to follow up analysis 
suggested that there may be significant predictors of loss to follow up which were not 
measured and thus not included in the models. One such factor may have been socio-
economic status. Data was collected on employment status only which may be a poor 
proxy for socio-economic status. Socio-economic status and education levels have been 
shown previously to be associated with survival [24, 25] and failing to control for this in 
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the current study may have limited the usefulness of the findings. Additionally, 
information on baseline opportunistic infections amongst participants was not available 
and as such could not be controlled for in any of the analyses. Other studies which had a 
lower proportion of women with AIDS-defining conditions at or before their first clinic 
visit showed baseline illnesses to be an important confounder in the relationship between 
gender and disease progression [8]. 
 
Adherence to antiretroviral treatment is an essential component of a successful HAART 
regimen and poor compliance with therapy may lead to development of drug-resistant 
virus. Adherence is very difficult to measure and it may significantly influence clinical 
deterioration. Studies investigating adherence and loss to follow up have shown women 
to be more prone to poor adherence and at higher risk of loss to follow up [37]. Our study 
suggested men were at higher risk of becoming lost to follow up than their female 
counterparts. However, adherence could not be estimated from the data and may have 
confounded the effect of gender on clinical and immunological outcomes. It is possible 
that the true effect of gender on clinical and immunological outcomes will not be 
uncovered until adherence can be reliably measured. 
 
There are no clear guidelines for South African patients regarding an acceptable weight 
gain within four months of initiating HAART. The studies reviewed showed mean weight 
gain of less than three kilograms within four months [21] but more than half of the 
individuals studied had baseline CD4 counts greater than 200/mm
3
 while the vast 
majority of patients in the Themba Lethu Clinical Cohort had baseline CD4 counts below 
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200/mm
3
 and thus may have been more likely to show more rapid weight gain initially. 
Additionally, using an absolute number as a cut-off for weight gain does not take into 
account an individuals starting weight or body type, consequently a weight gain of five 
percent or more within the first four months on treatment was chosen as the cutoff for 
weight gain as this corresponds with the weight loss that constitutes a WHO clinical stage 
1 criterion. However this cutoff still may not be appropriate and this lack of knowledge 
may be a limitation. The database did not contain any information on skin fold thickness 
or other anthropometric measurements such as waist or arm circumference and so 
lipodystrophic changes which certainly may have gender differences were not accounted 
for. 
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CHAPTER FIVE: CONCLUSIONS AND RECOMMENDATIONS 
 
The results of this study suggest that HIV-infected women may have an advantage over 
men with regard to clinical and immunological outcomes after initiation of antiretroviral 
treatment. In particular, men had higher mortality while women were more likely to show 
positive CD4 count response and to suppress HIV viral load after initiation on HAART.  
 
Currently there are still a significantly greater proportion of women accessing the 
treatment programme. Although it seems that the proportion of men enrolling onto 
treatment programmes is increasing, the findings of this study suggest that men present 
later to treatment programmes than women do and when they do present they may have 
more advanced disease, presenting with lower CD4 counts and more significant weight 
loss. To improve this situation, it is important that voluntary counseling and testing 
(VCT) programmes target men in their publicity campaigns. 
 
The establishment of “male-friendly” clinic practices may facilitate earlier VCT and 
access to antiretroviral therapy, and may also improve adherence amongst men. This 
could include after hours access, or weekend clinics as men were significantly more 
likely to be employed than women and work commitments may preclude regular visit to 
clinics for treatment.  Workplace facilities for VCT and alternate locations for obtaining 
treatment, such as a post office medication collection points, as has been successfully 
implemented in the Direct AIDS Intervention programme [38] through the non-profit 
organization, Right To Care, may also be useful.  
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. 
While the women had higher baseline CD4 counts than the men, their mean CD4 counts 
at initiation were still very low and all HIV-infected persons should be encouraged to 
access treatment early so that they may have opportunist infections treated promptly and 
maximize the full benefit of antiretroviral therapy.  
 
Attempts should be made to improve the lost to follow up rate once initiated on treatment 
and adherence promotion should occur regularly, particularly in the first six months after 
treatment initiation.  
 
This study considered relatively short-term outcomes after initiation on HAART and as 
the antiretroviral rollout programme matures, further research is needed to establish if 
gender differences persist after long term therapy so that appropriate interventions can be 
instituted to ensure all individuals receive maximum benefit from antiretroviral treatment 
programmes. 
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APPENDIX E 
Assumptions testing: 
Age distribution 
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Weight distribution 
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The histogram, box plot and 
normal probability plot all 
suggest a normal distribution of 
the continuous variables age 
(left) and weight (below). 
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CD4 count distribution 
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Time to death analysis 
Assumptions testing: 
Two of the covariates (sex and baseline CD4 count) violated the assumption of proportional 
hazard when using Schoenfeld residuals assessed statistically (test of Proportional hazards 
assumption p value = <0.001). However the graphical output suggests that the assumption is not 
violated. 
The histogram, box plot and 
normal probability plot all 
suggest the data is not of 
normal distribution for the 
continuous variable baseline 
CD4 count 
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Overall Model Fit 
 
The model was statistically significant and fit was tested. Martingale residuals and deviance 
residuals were calculated and plotted against survival time. Both confirmed that the Cox model fit 
the data fairly well.  
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Graph 1: stphplot 
Curve of category of sex versus 
log of analysis time. Parallel 
nature of plot suggests 
assumption of proportionality is 
not violated 
 
Graph 2 : stcoxkm 
Kaplan-Meier curves plotted 
against Cox predicted values for 
sibling mortality. Observed values 
are close to predicted values thus it 
is unlikely that the assumption of 
proportionality has been violated. 
 
0 = male 
1 = female 
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Lost to Follow up Analysis 
Assumptions testing: 
None of the covariates in the model for those with normal baseline BMI violated the assumption 
of proportional hazard when using Schoenfeld residuals assessed statistically (test of Proportional 
hazards assumption p value = 0.8992). The graphical output confirms that the assumption is not 
violated. 
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Graph 1: stphplot 
Curve of category of sex versus 
log of analysis time. Parallel 
nature of plot suggests 
assumption of proportionality is 
not violated 
 
Graph 2 : stcoxkm 
Kaplan-Meier curves plotted 
against Cox predicted values for 
sibling mortality. Observed 
values are close to predicted 
values thus it is unlikely that the 
assumption of proportionality has 
been violated. 
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Overall Model Fit 
 
The model was statistically significant and fit was tested. Martingale residuals and deviance 
residuals were calculated and plotted against survival time. Both suggested that the Cox model fit 
the data fairly poorly.  
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Death or Lost to Follow up Analysis 
Assumptions testing: 
All of the covariates violated the assumption of proportional hazard when using Schoenfeld 
residuals assessed statistically (test of Proportional hazards assumption p value = <0.0001). 
However the graphical output suggests that the assumption is not violated. 
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Overall Model Fit 
The model was statistically significant and fit was tested. Martingale residuals and deviance 
residuals were calculated and plotted against survival time. Both suggested that the Cox model fit 
the data fairly poorly.  
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Graph 1: stphplot 
Curve of category of sex versus 
log of analysis time. Parallel 
nature of plot suggests 
assumption of proportionality is 
not violated 
 
Graph 2 : stcoxkm 
Kaplan-Meier curves plotted against 
Cox predicted values for sibling 
mortality. Observed values are close to 
predicted values thus it is unlikely that 
the assumption of proportionality has 
been violated. 
0 = male 
1 = female 
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Time to 100 cell increase in CD4 count analysis 
Assumptions testing: 
None of the covariates violated the assumption of proportional hazard when using Schoenfeld 
residuals assessed statistically (test of Proportional hazards assumption p value = 0.6315) and 
graphically. The graphical output is presented below. 
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Overall Model Fit 
 
Graph 1: stphplot 
Curve of category of sex versus 
log of analysis time. Parallel 
nature of plot suggests 
assumption of proportionality is 
not violated 
 
Graph 2 : stcoxkm 
Kaplan-Meier curves plotted 
against Cox predicted values for 
sibling mortality. Observed values 
are close to predicted values thus it 
is unlikely that the assumption of 
proportionality has been violated. 
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The model was statistically significant and fit was tested. Martingale residuals and deviance 
residuals were calculated and plotted against survival time. Both confirmed that the Cox model fit 
the data fairly well.  
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CD4 Cell count analysis 
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The Shapiro-Wilk test for normal data suggests that the CD4 count at 4 months was not 
normally distributed. However, the graphical output (histogram and normal distribution 
probability plots), suggested that the large sample size tends the data towards normal 
distribution. 
 
Time to first ever HIV viral load suppression analysis 
Assumption testing 
Assumptions testing: 
None of the covariates violated the assumption of proportional hazard when using Schoenfeld 
residuals assessed statistically (test of Proportional hazards assumption p value = 0.4002) and 
graphically. The graphical output is presented below. 
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Overall Model Fit 
 
The model was statistically significant and fit was tested. Martingale residuals and deviance 
residuals were calculated and plotted against survival time. These residual plots suggest the 
model fit could have been better.  
Graph 1: stphplot 
Curve of category of sex versus 
log of analysis time. Parallel 
nature of plot suggests 
assumption of proportionality is 
not violated 
 
Graph 2 : stcoxkm 
Kaplan-Meier curves plotted 
against Cox predicted values for 
sibling mortality. Observed values 
are close to predicted values thus it 
is unlikely that the assumption of 
proportionality has been violated. 
 
0 = male 
1 = female 
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